Prism Medico Reports Strong Quarterly Performance Amid Long-Term Profitability Challenges

Prism Medico & Pharmacy, operating within the Non-Banking Financial Company (NBFC) sector, has recently undergone an evaluation adjustment that reflects notable shifts in its financial metrics. The company reported a positive financial performance for the quarter ending June 2025, with key indicators reaching new highs. Specifically, the Profit Before Depreciation, Interest, and Taxes (PBDIT) stood at Rs 0.65 crore, while the Profit After Tax (PAT) also peaked at Rs 0.66 crore. Additionally, the Earnings Per Share (EPS) reached Rs 1.09, showcasing a strong quarter.
Despite these positive results, the company has faced challenges over the longer term, including a decline in operating profits with a -0.20% CAGR over the past five years. The EBIT to Interest ratio indicates difficulties in servicing debt, reflecting a ratio of -0.03. Furthermore, the Return on Equity (ROE) remains low at 0.59%, suggesting limited profitability relative to shareholders' funds.

In light of these developments, Prism Medico's evaluation has been adjusted, indicating a revision in its score. The stock currently trades at Rs 14.61, with a previous close of Rs 13.18, and has experienced significant fluctuations over the past year.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.